Why is Regeneron Pharmaceuticals stock surging today?

Truist Securities reaffirmed its Buy rating on Regeneron Pharmaceuticals and raised its price target to $982 from $780, citing a 5.8% upside from the Oct 30 close. Recent analyst notes have price targets ranging from $925 to $1175.

Truist raised its price target on Regeneron (NASDAQ:REGN) to $982 from $780, citing strong Q3 results. Revenue grew 18.6% to $16.9B. Several analysts revised earnings upwards. Upcoming catalysts include drug decisions and data releases. REGN shares are near a 52-week high, up 15% in the past week.

Guggenheim reaffirmed its Buy rating for Regeneron Pharmaceuticals and increased its price target to $1100 from $1030, citing a 6.8% increase. This target suggests an 18.5% upside from the Oct 30 close of $927.89. Recent analyst price targets for the company range from $875 to $1175.

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

Regeneron reported Q3 2026 revenue of $5.12B, up 36% YoY, beating estimates. Non-GAAP EPS rose 70% to $20.07, GAAP EPS up 35% to $18.45. Shares closed 13% higher at $927.89. Growth driven by Sanofi collaboration and Eylea HD.